Citation

Wistedt B. Nord. J. Psychiatry 1991; 45(S24): 3-4.

Copyright

(Copyright © 1991, Informa - Taylor and Francis Group)

DOI

10.3109/08039489109096676

PMID

unavailable

Abstract

When a new antidepressant drug is introduced, our possibilities to give our patients a more specific treatment are increased. At the same time, however, the demands for knowledge are increased. Thus, a new drug for the treatment of depression such as mianserin ought to be introduced as a result of an open-minded clinical discussion. The new drug must be compared with already available drugs as concerns mechanism of action, indications, clinical profile, side effects and so on. In the present symposium, Odd Lingjærde will discuss the mechanism of action of antidepressants, Roger Pinder the pharmacology and clinical effects of mianserin, Stuart Montgomery the cost-benefit aspects, Ulrik Malt the use of mianserin in patients with psychosomatic disorders, and Lars von Knorring the risk of suicide in depressed patients and possible ways to reduce the risk of suicide. The symposium is organized in cooperation with Organon Pharmaceuticals. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

Language: sv

Keywords

human; depression; editorial; moclobemide; mianserin; Side effects; Clinical profile; New antidepressants